$107.72
-0.19 (-0.18%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where KMB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 8 observational · 3 with posted results
Held by 16 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, Squarepoint Ops LLC, CITADEL ADVISORS LLC, AQR CAPITAL MANAGEMENT LLC, +11 more) · FINRA short interest 14.7 days to cover (settled 2026-07-31) · government filings 180d: 0 congress / 8 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Tampon Safety-in-Use StudyNCT07561905Incidence of Tampon Related Adverse EventsOpen-label · Other | Not applicable | Recruiting | Device: Tampon A | Menstruation | 60 | 2026-08-31 | in 12 d | 2026-08-10 |
| Tampon Design Validation StudyNCT05553600results2024-01-17The Percentage of Used Tampons That Have ElongatedRandomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Tampon BR, Tampon CR, Tampon BS, Tampon CS | Menstruation | 732 | 2023-05-05actual | — | 2024-01-17 |
| Effect of Use of DryNites Absorbent Pants on the Rate of Spontaneous Resolution of Paediatric Nocturnal Enuresis (NE)NCT04620356results2024-12-06Wet NightsRandomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: DryNites Pyjama Pants | Nocturnal Enuresis | 105 | 2023-01-28actual | — | 2024-12-06 |
| Project SHARE (motherS Have All the Right microbEs)NCT03239197observationalMaternal staphylococci is transferred to infant during and following birth. | — | Withdrawnsponsor's stated reason: Sponsor request | — | Microbiota | 0 | Mar 2018 | — | 2017-12-12 |
| Effect of Baby Wipe Solutions on Fecal Enzyme-induced IrritationNCT03346447observationalErythema | — | Completed | Other: Artificial Fecal Enzyme | Skin Health | 23 | 2017-10-27actual | — | 2018-01-18 |
| Micro-Technique SamplingNCT03242577observationalBest method for collecting skin microbiome samples | — | Completed | — | Dermatitis | 10 | 2017-08-02actual | — | 2017-11-01 |
| BM Characterization PilotNCT03138057observationalTo determine enzymes in infant stools | — | Completed | — | Diaper Rash | 25 | 2017-06-12actual | — | 2018-01-18 |
| Rudolph: Nasal Microbiota With Red and Sore NoseNCT03073837nasal microbiota composition and occurrence of nose redness and soreness during rhinovirus infectionOpen-label · Basic science | Not applicable | Completed | Other: Rhinovirus Challenge | Dermatitis | 10 | 2017-04-18actual | — | 2017-08-18 |
| Infant Fecal Insult StudyNCT02979210Type of microbes present on skin after exposure to artificial fecal insultOpen-label · Basic science | Not applicable | Completed | Other: Artificial Fecal Insult, Phosphate Buffered Saline | Dermatitis | 24 | 2017-01-26actual | — | 2017-08-18 |
| Infant Microbiome in Diaper RashNCT02893501observationalOperational Taxonomic Units (OTUs) of microbes present on skin | — | Completed | — | Diaper Rash | 25 | 2017-01-04actual | — | 2017-08-18 |
| BM Collection From NICU Infants for CompositionNCT02570698observationalComposition of proteins (ug/uL) in premature infant feces | — | Completed | — | Diaper Dermatitis | 25 | 2016-12-07actual | — | 2017-08-18 |
| Nasal Swab Study to Explore the Nasal MicrobiaNCT02535442observationalType and amount of nasal microbes | — | Completed | — | Common Cold | 42 | Apr 2016actual | — | 2016-07-04 |
| Ex Vivo High-Throughput Assay for Vaginal Community Post-menopausal WomenNCT02415868observationalCharacterization of the microbiota | — | Completed | — | Postmenopausal Syndrome | 10 | Feb 2016actual | — | 2016-02-23 |
| A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to SurfactantsNCT02615912Type of microbes present on skin after exposure to various surfactantsOpen-label · Basic science | Not applicable | Completed | Other: PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%, Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%, Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%, Silwet* DA-63 (Momentive) 1.5%, Sodium lauryl sulfate (Sigma Aldrich) 1.0%, Water (control) | Dermatitis | 24 | Dec 2015actual | — | 2016-09-28 |
| Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14NCT02139839Change from baseline Nugent Score (arbitrary units) after treatment versus Change from baseline Nugent Score after placeboRandomized · Quadruple-masked · Treatment | Early Phase 1 | Completed | Other: Lactobacillus capsules · Drug: Placebo gelatin pill | Vaginosis, Bacterial | 14 | Mar 2013actual | — | 2014-05-15 |
| Study of the Combination of a Cyanoacrylate and Surgical Solutions in Reducing Skin Flora ContaminationNCT00467857results2011-02-11Change in Number of Unique Bacterial Isolates From Pre-skin Preparation to Post-CABG - Sternal SiteRandomized · Open-label · Prevention | Phase 4 | Completed | Procedure: InteguSeal* skin sealant and standard surgical preparation · Other: Standard preoperative skin preparation | Skin Flora Contamination | 293 | Mar 2009actual | — | 2012-09-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19